Trial Profile
A randomized, double-blind, phase III comparative trial of 2 doses of ZD1839 (IRESSA) [gefitinib] in combination with paclitaxel and carboplatin versus placebo in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced (stage III or IV) non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2005
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Paclitaxel
- Indications Lung cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms INTACT-2
- Sponsors AstraZeneca
- 04 Sep 2005 New trial record.